Baladi: Brazil After Approval, Before Proof
The Ministry of Agriculture approval in February 2026 removed one bottleneck in the Brazil project, but it did not complete the operating path. Baladi has already funded about NIS 16 million out of its expected NIS 21 million share without receiving ownership in the plant and without yet disclosing the payback economics.
What Actually Changed After Approval
The main article argued that Brazil is the proof layer in Baladi's 2026 story. This follow-up isolates the point after the Ministry of Agriculture approval and before commercial proof. The reason is simple: in February 2026 one meaningful regulatory bottleneck was removed, but as of the annual report's approval date the full operating chain was still not closed, while most of the cash was already out.
The approval Baladi received on February 12, 2026 did one clear thing: it placed the Brazilian plant on the list of facilities approved for poultry imports into Israel. That was a material step because the administrative petition filed on January 25, 2026 was built precisely around the claim that the required Brazilian regulatory approvals had already been delivered, that the Israeli process was stuck at a technical stage, and that further delay was preventing the company from monetizing an investment that had already been mostly made. But that same approval did not instantly turn Brazil into an earnings engine. The Ministry of Agriculture set the decision to become effective only on June 15, 2026 in order to allow preparation time, and the company itself wrote that it would try to bring that date forward.
That means Baladi has moved from a world of maybe it will not be approved, to a tougher world: it was approved, now it has to prove that it works. That is an important shift. The market no longer has to debate whether a regulatory opening exists in principle. It has to judge how long it will take before that opening becomes actual imports, actual marketing in Israel, and ultimately investment recovery.
| Layer | What has already happened | What is still open | Why it matters |
|---|---|---|---|
| Adaptation work | Most of the investments were completed, and after the balance-sheet date the production lines and initial trial activities were completed | There are still no disclosed import, sales, or profitability figures | Until the project moves from setup to a stream of orders, the investment remains funded but unproven |
| Ministry of Agriculture | On February 12, 2026 the plant was approved for the import list | The approval only becomes effective on June 15, 2026 | There is approval, but there is also a waiting period that leaves the project without revenue while the capital has already been committed |
| Kashrut | A High Court track remains active and the company continues to argue that the path to a kashrut certificate must be formalized | As of the approval date of the annual report, there was still no final ruling | Even after the Ministry of Agriculture approval, the kosher operating path was not yet fully closed |
| Investment recovery | Baladi's expected share stands at about NIS 21 million, and about NIS 16 million had already been transferred during the reporting period | There is no disclosure on minimum volume, target margin, or payback period | Without unit-economics disclosure, proof can only come from actual execution |
The Economics of the Contract: Investment Without Ownership, Exclusivity Without Guaranteed Volume
This is the core of the continuation analysis. Baladi did not buy a plant in Brazil. It funded commercial access to a supplier's plant. Note 20(c)(2) says this very clearly: the company and the supplier will invest in the supplier's facilities for improvements and adjustments, but Baladi's investment does not grant it any right in the plant, in the supplier's shares, or in any other equity asset. That is not a legal footnote. It is an economic conclusion.
In other words, the NIS 21 million Baladi committed to invest does not create ownership, control, or collateral. It is meant to buy two other layers of value: the ability to activate production lines capable of making kosher poultry for the Israeli market, and the exclusive right to import and market those products in Israel. If the project works, that can be commercially meaningful. Until then, however, this is a commercial investment whose recovery depends entirely on the ability to generate a lasting stream of orders.
The filings do not provide the comfort numbers an investor would want. There is no disclosure on purchase price per unit, expected gross margin, minimum order volume, planned rollout pace, or payback period. What the company does provide is a clear contractual mechanism: after the adaptations are completed, Baladi will purchase the products according to orders it places from time to time and under a price list agreed between the parties. That wording matters because it makes clear that the agreement provides a framework and exclusivity, but does not force any specific level of activity.
| Economic clause | What the agreement says | What it means in practice |
|---|---|---|
| Investment structure | Baladi is expected to invest about NIS 21 million, and about NIS 16 million had already been transferred during the reporting period | Most of the cash has already gone out before imports have started |
| Ownership | The investment does not grant Baladi rights in the plant, in the supplier's shares, or in other assets | Recovery cannot come from selling an asset. It can only come from successful commercial activity |
| Exclusivity | Baladi is meant to import and market the products exclusively in Israel | If the project works, the company holds a strong commercial right. If not, exclusivity alone has limited value |
| Purchase mechanism | Purchases are to be made under orders that Baladi will place from time to time and under a price list set between the parties | The filings provide no anchor for minimum volume or guaranteed sales pace |
| Contract term | Five years from signing, with two additional five-year option periods | There is a long commercial runway, but it only has value if the initial activation works |
| Governing law | The agreement is governed by the laws of England and Wales | Enforcement and interpretation sit outside Israel |
| Supplier termination right | The supplier may cancel on six months' prior notice and in that case return the proportional part of Baladi's investment, up to the amount invested | Baladi has partial downside protection, but not full certainty |
| Baladi termination right | A cancellation by the company does not entitle it to recover the investment or any part of it | The economic downside of stopping the project sits mainly with Baladi |
That table tells a simple story: Baladi bought a strong commercial option, not industrial ownership. The test of success here is therefore not whether the plant exists or whether approval was granted, but whether exclusivity turns into revenue and profit.
June 15, 2026 Is a Starting Line, Not a Finish Line
The natural temptation is to read June 15, 2026 as a launch date. That is only a partial read. For Baladi, it is at most the date on which the import lane opens from the Ministry of Agriculture side, unless that date is brought forward first. The filings themselves show that the company is still operating on two separate tracks: the administrative track with the Ministry of Agriculture, and the halachic track with the Chief Rabbinate.
The January 2026 administrative petition argued that most of the adaptation work had already been completed, that the required approvals from Brazil had already been delivered, and that further Israeli delay was harming the company's ability to begin operating. That is exactly why the company wrote at the time that the continuing legal process could affect the start of the kashrut teams' activity at the plant and the marketing effort in Israel. The approval granted in February solved part of that problem, but the annual report does not present the story as if everything is now behind it. Quite the opposite: in Note 20(c)(2), the company still describes an active High Court process around the ability to issue a kashrut certificate for poultry from the Brazilian plant, and states that as of the report approval date no final ruling had yet been received.
That is the most important point from here. Brazil is no longer a question of intent. It is a question of execution sequence. For the investment to start behaving like an economic asset, it is not enough for one ministry to have granted approval in principle or for an effective date to have been set. The whole chain has to move from legal and preparation mode into repeat commercial activity. Until that happens, the NIS 21 million remains above all a test of patience and managerial discipline.
What Would Count as Proof, and What the Filing Still Does Not Show
This is also the answer to the before proof framing. The report gives no sales target, no profitability target, and no timetable for recovering the investment. That means proof will not come from one accounting table. It will come from a sequence of operating and commercial signs that the market will need to see in order.
The first sign is that the June 15, 2026 effective date actually holds, or is accelerated. The second sign is that the halachic track stops being an active bottleneck. The third, and most important, is the appearance of actual imports and actual marketing in Israel, rather than yet another update about committees, procedures, and letters. The fourth sign is more indirect but still important: only once the project shifts into repeat commercial activity will it be possible to judge whether the contractual refund mechanism available to Baladi if the supplier terminates is meaningful protection, or mainly partial consolation.
It is also important to say what the filing does not allow anyone to know. There is no basis here to calculate return on investment, no basis to estimate breakeven, and no basis to decide whether exclusivity in Israel is likely to translate into superior margin or merely more volume. Anyone trying to derive payback figures already is pushing the filing past what it actually says. What the filing does allow is a cleaner conclusion: the investment has advanced faster than the economic proof, and 2026 has to work hard to close that gap.
Conclusion
The Brazil story changed in February 2026, but it did not finish. A major regulatory barrier was removed, most of the money has already been invested, and the production lines have already moved into an advanced stage. That is much more than Baladi had a year earlier. At the same time, Baladi still does not own the plant, still does not disclose the payback economics, and still has not fully closed the kosher operating path. That is why June 15, 2026 is an important date, but important as a test point, not as proof of success.
Follow-up thesis: after the approval, Brazil looks less like a regulatory gamble and more like a large commercial investment that is already sitting on the balance sheet, but is still waiting for proof of activation, volume, and recovery.
If over the next two to four quarters Baladi shows that the approval becomes effective on time, that the halachic bottleneck progresses, and that the project moves into actual imports and actual marketing, the reading of the investment will change materially. If the legal tracks continue, or if activity is delayed even after the administrative lane opens, the money already sent to Brazil will look less like a growth engine and more like capital that left too early relative to the maturity of the project.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.